870487-10-8

Basic information

• Product Name: Boc-Val-Cit-PAB-PNP
• Synonyms: Boc-Val-Cit-PAB-PNP;BOC-Val-cit-pab
• CAS NO: 870487-10-8
• Molecular Formula: C₃₀H₄₀N₆O₁₀
• Molecular Weight: 644.6728
• EINECS: -0
• Product Categories: Linker;ADC LINKER
• Mol File: 870487-10-8.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 896.0±65.0 °C(Predicted)
• Appearance: /
• Density: 1.291±0.06 g/cm3(Predicted)
• PKA: 11.25±0.46(Predicted)
• CAS DataBase Reference: Boc-Val-Cit-PAB-PNP(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Val-Cit-PAB-PNP(870487-10-8)
• EPA Substance Registry System: Boc-Val-Cit-PAB-PNP(870487-10-8)

Safety Data

• Hazardous Substances Data: 870487-10-8(Hazardous Substances Data)

Usage

Description

Boc-Val-Cit-PAB-PNP is a cleavable peptide ADC linker that is designed to facilitate the targeted delivery of therapeutic agents to cancer cells. The Val-Cit sequence within the linker is specifically cleaved by the enzyme Cathepsin B, which is predominantly found in the lysosome. This selective cleavage ensures that the ADC payload is released only within the cell, thereby minimizing potential side effects on healthy cells. Furthermore, the PAB-PNP component of the linker can be substituted with amine-bearing molecules, allowing for the customization of the linker to suit specific therapeutic applications.

Uses

Used in Pharmaceutical Industry:
Boc-Val-Cit-PAB-PNP is used as a cleavable peptide ADC linker for the targeted delivery of therapeutic agents to cancer cells. Its specific cleavage by Cathepsin B ensures that the ADC payload is released only within the lysosome of cancer cells, minimizing potential side effects on healthy cells.
Used in Cancer Therapy:
Boc-Val-Cit-PAB-PNP is used as a component of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. The selective cleavage of the Val-Cit sequence by Cathepsin B allows for the precise release of the ADC payload within cancer cells, enhancing the therapeutic efficacy and reducing side effects.
Used in Drug Delivery Systems:
Boc-Val-Cit-PAB-PNP is used in the development of drug delivery systems that aim to improve the bioavailability and therapeutic outcomes of cancer treatments. The customizable nature of the linker allows for the attachment of various amine-bearing molecules, enabling the design of targeted drug delivery systems that can effectively reach and treat cancer cells.

Upstream product

• 133174-15-9 (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid 
• 870487-09-5 tert-butyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentane-2-yl)amino)-3-methyl-1-oxobutane-2-yl)carbamate 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 3392-12-9 Boc-Val-ONSu 
• 93964-78-4 methyl (S)-2-amino-5-ureidopentanoate hydrochloride 
• 623-04-1 4-aminobenzenemethanol 
• 372-75-8 Citrulline 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 870487-08-4 (6S,9S)-1-amino-9-isopropyl-13,13-dimethyl-1,8,11-trioxo-12-oxa-2,7,10-triazatetradecane-6-carboxylic acid 

Relevant articles and documents

TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF A HEPATOCELLULAR RECEPTOR A2 PRODUCING ERYTHROPOIETIN (EPHA2)

The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

BICYCLE TOXIN CONJUGATES AND USES THEREOF

The present invention relates to Bicycle toxin conjugates, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof for preventing or treating a disease, disorder, or condition characterised by overexpression

BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.